NCT06895408

Separate and Combined Extrapancreatic Effects of GIP and GLP-1

Separate and Combined Extrapancreatic Effects of Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide 1 (GLP-1)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: University Hospital, Gentofte, Copenhagen · Academic / Other
• Sex: All
• Age: 30 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The two gut-derived hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are secreted from intestinal cells in relation to a meal and increase insulin secretion from the pancreas. The hormones also exert effects outside the pancreas, but especially for GIP, these are poorly investigated. Because of this, only GLP-1 based drugs (GLP-1 receptor agonists) are on the market for the treatment of type 2 diabetes and obesity. Nonetheless, a new drug is in clinical development: a combined GIP-GLP-1-receptor agonist (tirzepatide), which has shown better results than GLP-1 alone. The mechanism behind these impressive effects are unknown and in this study, the investigators will look into the exptrapancreatic effects of GIP and GLP-1, separate and combined and thus elucidate the mechanisms of action of this new drug class.

Conditions

• Pancreatectomy; Hyperglycemia

Interventions

Type	Name	Description
OTHER	Intravenous Infusion	Glucose-dependent Insulinotropic Polypeptide
OTHER	Intravenous Infusion	Glucagon-Like Peptide 1
OTHER	Intravenous Infusion	Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide 1
OTHER	Intravenous Infusion	Saline

Timeline

• Start date: 2025-02-19
• Primary completion: 2025-07-14
• Completion: 2025-07-14
• First posted: 2025-03-26
• Last updated: 2025-09-09

Locations

1 site across 1 country: Denmark